Prospective Grant of Exclusive License: Use of a Complete T-Cell Receptor Recognizing MART-1 Peptide Restricted by HLA-A2, Incorporated in a Continuous T-Lymphocyte Cell Line Developed or Owned by Licensee To Treat Cancer, 54297 [E6-15216]
Download as PDF
<![CDATA[
Federal Register / Vol. 71, No. 178 / Thursday, September 14, 2006 / Notices
trade secrets or commercial property
such as patentable material, and
personal information concerning
individuals associated with the grant
applications, the disclosure of which
constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: NIDCR Special Grants
Review Committee, 07–01, Review RO3s, Ks,
Fs.
Date: October 12–13, 2006.
Time: 8 a.m. to 5 p.m.
Agenda: To review and evaluate grant
applications.
Place: Clarion Hotel Bethesda Park, 8400
Wisconsin Avenue, Bethesda, MD 20814.
Contact Person: Raj K. Krishnaraju, Ph.D.,
MS, Scientific Review Administrator,
Scientific Review Branch, National Inst of
Dental & Craniofacial Research, National
Institutes of Health, 45 Center Dr. Rm 4AN
32J, Bethesda, MD 20892. 301–594–4864.
kkrishna@nidcr.nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.121, Oral Diseases and
Disorders Research, National Institutes of
Health, HHS).
Dated: September 5, 2006.
Anna Snouffer,
Acting Director, Office of Federal Advisory
Committee Policy.
[FR Doc. 06–7628 Filed 9–13–06; 8:45 am]
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
Prospective Grant of Exclusive
License: Use of a Complete T-Cell
Receptor Recognizing MART–1
Peptide Restricted by HLA–A2,
Incorporated in a Continuous TLymphocyte Cell Line Developed or
Owned by Licensee To Treat Cancer
National Institutes of Health,
Public Health Service, HHS.
ACTION: Notice.
rwilkins on PROD1PC63 with NOTICES
AGENCY:
SUMMARY: This notice, in accordance
with 35 U.S.C. 209(c)(1) and 37 CFR
part 404.7(a)(1)(i), that the National
Institutes of Health, Department of
Health and Human Services, is
contemplating the grant of an exclusive
patent license to practice the inventions
embodied in U.S. patent 5,830,755 filed
March 27, 1995 [HHS Ref. No. E–093–
1995/0–US–01] and Australian Patent
709122 filed March 27, 1996 [HHS Ref.
No. E–093–1995/0–AU–03], entitled TCell Receptors and Their Use in
Therapeutic and Diagnostic Methods, to
CellCure A/S, which is located in
Aarhus, Denmark. The patent rights in
these inventions have been assigned to
the United States of America.
VerDate Aug<31>2005
20:23 Sep 13, 2006
Jkt 208001
The prospective exclusive license
territory may be worldwide and the
field of use may be limited to the use
of a complete T-cell receptor MART–1
peptide restricted by HLA–A2
incorporated into a continuous TLymphocyte cell line developed or
owned by licensee to treat cancer.
Date: September 7, 2006.
Steven M. Ferguson,
Director, Division of Technology Development
and Transfer, Office of Technology Transfer,
National Institutes of Health.
[FR Doc. E6–15216 Filed 9–13–06; 8:45 am]
Only written comments and/or
applications for a license which are
received by the NIH Office of
Technology Transfer on or before
November 13, 2006 will be considered.
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Requests for copies of the
patent application, inquiries, comments,
and other materials relating to the
contemplated exclusive license should
be directed to: Michelle A. Booden,
Ph.D., Technology Licensing Specialist,
Office of Technology Transfer, National
Institutes of Health, 6011 Executive
Boulevard, Suite 325, Rockville, MD
20852–3804; telephone: (301) 451–7337;
facsimile: (301) 402–0220; e-mail:
boodenm@mail.nih.gov.
Agency Information Collection
Activities: Submission for OMB
Review; Comment Request
The
technology describes the composition
and use of nucleic acid sequences that
encode polypeptides capable of forming
a T-cell receptor (TCR) in a genetically
engineered cell. Specifically, these
nucleic acid sequences will encode
TCR’s specific to tumor associated
antigens (TAA), MART–1. T-Cells
engineered with these tumor associated
antigen specific TCRs show specific
immune responses against TAA
expressing cancer cells. Additionally, a
method of treating or preventing cancer
by administrating the above described
TCRs is also disclosed.
The prospective exclusive license will
be royalty bearing and will comply with
the terms and conditions of 35 U.S.C.
209 and 37 CFR part 404.7. The
prospective exclusive license may be
granted unless within sixty (60) days
from the date of this published notice,
the NIH receives written evidence and
argument that establishes that the grant
of the license would not be consistent
with the requirements of 35 U.S.C. 209
and 37 CFR part 404.7.
Applications for a license in the field
of use filed in response to this notice
will be treated as objections to the grant
of the contemplated exclusive license.
Comments and objections submitted to
this notice will not be made available
for public inspection and, to the extent
permitted by law, will not be released
under the Freedom of Information Act,
5 U.S.C. 552.
Project: Measures of Co-Occurring
Infrastructure—NEW
SAMHSA’s Center for Mental Health
Services and Center for Substance
Abuse Treatment will implement
provider-level performance measures
about the screening, assessment, and
treatment of co-occurring disorders.
Implementation will be limited to the 15
current States with Co-occurring State
Incentive Grants (COSIG), and States
receiving COSIG grants in 2006 and
future years. SAMHSA anticipates
awarding two COSIG grants in 2006.
COSIG grants enable States to develop
or enhance their infrastructure and
capacity to provide accessible, effective,
comprehensive, coordinated/integrated,
and evidence-based treatment services
to persons with co-occurring substance
abuse and mental disorders. Only the
immediate Office of the Governor of
States may receive COSIG grants,
because SAMHSA considers the Office
of the Governor to have the greatest
potential to provide the multi-agency
leadership needed to accomplish COSIG
goals. The COSIG program is part of
SAMHSA plan to achieve certain goals
regarding services for persons with cooccurring substance use and mental
disorders:
• Increase percentage of treatment
programs that screen for co-occurring
disorders;
• Increase percentage of treatment
programs that assess for co-occurring
disorders;
• Increase percentage of treatment
programs that treat co-occurring
disorders through collaborative,
DATES:
ADDRESSES:
SUPPLEMENTARY INFORMATION:
BILLING CODE 4140–01–M
54297
PO 00000
Frm 00035
Fmt 4703
Sfmt 4703
BILLING CODE 4167–01–P
Substance Abuse and Mental Health
Services Administration
Periodically, the Substance Abuse and
Mental Health Services Administration
(SAMHSA) will publish a summary of
information collection requests under
OMB review, in compliance with the
Paperwork Reduction Act (44 U.S.C.
Chapter 35). To request a copy of these
documents, call the SAMHSA Reports
Clearance Officer on (240) 276–1243.
E:\FR\FM\14SEN1.SGM
14SEN1
]]>Agencies
[Federal Register Volume 71, Number 178 (Thursday, September 14, 2006)]
[Notices]
[Page 54297]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: E6-15216]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
Prospective Grant of Exclusive License: Use of a Complete T-Cell
Receptor Recognizing MART-1 Peptide Restricted by HLA-A2, Incorporated
in a Continuous T-Lymphocyte Cell Line Developed or Owned by Licensee
To Treat Cancer
AGENCY: National Institutes of Health, Public Health Service, HHS.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: This notice, in accordance with 35 U.S.C. 209(c)(1) and 37 CFR
part 404.7(a)(1)(i), that the National Institutes of Health, Department
of Health and Human Services, is contemplating the grant of an
exclusive patent license to practice the inventions embodied in U.S.
patent 5,830,755 filed March 27, 1995 [HHS Ref. No. E-093-1995/0-US-01]
and Australian Patent 709122 filed March 27, 1996 [HHS Ref. No. E-093-
1995/0-AU-03], entitled T-Cell Receptors and Their Use in Therapeutic
and Diagnostic Methods, to CellCure A/S, which is located in Aarhus,
Denmark. The patent rights in these inventions have been assigned to
the United States of America.
The prospective exclusive license territory may be worldwide and
the field of use may be limited to the use of a complete T-cell
receptor MART-1 peptide restricted by HLA-A2 incorporated into a
continuous T-Lymphocyte cell line developed or owned by licensee to
treat cancer.
DATES: Only written comments and/or applications for a license which
are received by the NIH Office of Technology Transfer on or before
November 13, 2006 will be considered.
ADDRESSES: Requests for copies of the patent application, inquiries,
comments, and other materials relating to the contemplated exclusive
license should be directed to: Michelle A. Booden, Ph.D., Technology
Licensing Specialist, Office of Technology Transfer, National
Institutes of Health, 6011 Executive Boulevard, Suite 325, Rockville,
MD 20852-3804; telephone: (301) 451-7337; facsimile: (301) 402-0220; e-
mail: boodenm@mail.nih.gov.
SUPPLEMENTARY INFORMATION: The technology describes the composition and
use of nucleic acid sequences that encode polypeptides capable of
forming a T-cell receptor (TCR) in a genetically engineered cell.
Specifically, these nucleic acid sequences will encode TCR's specific
to tumor associated antigens (TAA), MART-1. T-Cells engineered with
these tumor associated antigen specific TCRs show specific immune
responses against TAA expressing cancer cells. Additionally, a method
of treating or preventing cancer by administrating the above described
TCRs is also disclosed.
The prospective exclusive license will be royalty bearing and will
comply with the terms and conditions of 35 U.S.C. 209 and 37 CFR part
404.7. The prospective exclusive license may be granted unless within
sixty (60) days from the date of this published notice, the NIH
receives written evidence and argument that establishes that the grant
of the license would not be consistent with the requirements of 35
U.S.C. 209 and 37 CFR part 404.7.
Applications for a license in the field of use filed in response to
this notice will be treated as objections to the grant of the
contemplated exclusive license. Comments and objections submitted to
this notice will not be made available for public inspection and, to
the extent permitted by law, will not be released under the Freedom of
Information Act, 5 U.S.C. 552.
Date: September 7, 2006.
Steven M. Ferguson,
Director, Division of Technology Development and Transfer, Office of
Technology Transfer, National Institutes of Health.
[FR Doc. E6-15216 Filed 9-13-06; 8:45 am]
BILLING CODE 4167-01-P
